Key points are not available for this paper at this time.
Abstract Humans are chronically exposed to furan, a potent liver toxicant and carcinogen that occurs in a variety of heat-processed foods. Assessment of human exposure based on the furan content in foods is, however, subject to some uncertainty due to the high volatility of furan. Biomarker monitoring is thus considered an alternative or complementary approach to furan exposure assessment. Previous work suggested that urinary furan metabolites derived from the reaction of cis -2-butene-1,4-dial (BDA), the reactive intermediate of furan, with glutathione (GSH) or amino acids may serve as potential biomarkers of furan exposure. However, some metabolites were also reported to occur in urine of untreated animals, indicating either background contamination via animal feed or endogenous sources, which may limit their suitability as biomarkers of exposure. The overall aim of the present study was to accurately establish the correlation between external dose and concentration of furan metabolites in urine over time and to discriminate against endogenous formation and furan intake via feed. To this end, the furan metabolites GSH-BDA ( N -4-carboxy-4-(3-mercapto-1 H -pyrrol-1-yl)-1-oxobutyl-L-cysteinylglycine), NAcLys-BDA ( R -2-(acetylamino)-6-(2,5-dihydro-2-oxo-1 H -pyrrol-1-yl)-1-hexanoic acid), NAcCys-BDA-NAcLys ( N -acetyl-S-1-[5-(acetylamino)-5-carboxypentyl-1 H -pyrrol-3-yl]-L-cysteine) and NAcCys-BDA-NAcLys sulfoxide ( N -acetyl-S-1-[5-(acetylamino)-5-carboxypentyl-1 H -pyrrol-3-yl]-L-cysteine sulfoxide) were simultaneously analyzed by stable isotope dilution ESI–LC–MS/MS as unlabeled and 13 C 4 -furan dependent metabolites following oral administration of a single oral dose of isotopically labelled 13 C 4 -furan (0.1, 1, 10, 100 and 1000 µg/kg bw) to male and female F344/DuCrl rats. Although a linear correlation between urinary excretion of 13 C 4 -furan-dependent metabolites was observed, analysis of unlabeled NAcLys-BDA, NAcCys-BDA-NAcLys and NAcCys-BDA-NAcLys sulfoxide revealed substantial, fairly constant urinary background levels throughout the course of the study. Analysis of furan in animal feed excluded feed as a source for these background levels. GSH-BDA was identified as the only furan metabolite without background occurrence, suggesting that it may present a specific biomarker to monitor external furan exposure. Studies in humans are now needed to establish if analysis of urinary GSH-BDA may provide reliable exposure estimates.
Kalisch et al. (Thu,) studied this question.